TheEdgeResearch
Home / Stocks / CHGCF

Chugai Pharmaceutical Co., Ltd. (CHGCF)

OTC Healthcare Drug Manufacturers - General
$44.81 ▲ +1.10%
Market Cap
$73.75B
Sector
Healthcare
Industry
Drug Manufacturers - General
Beta
0.55
52-Wk Range
34.788-68.08
CEO
Osamu Okuda
Country
JP
Currency
USD

Chugai Pharmaceutical Co., Ltd. operates in the Drug Manufacturers - General industry of the Healthcare sector, headquartered in Tokyo, TY, JP. The stock last traded at $44.81, up 1.10% on the session, giving a market capitalisation of $73.75B. On trailing twelve-month figures it carries a trailing P/E of 23.23, a net margin of 35.6%. Its beta of 0.55 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
23.23
Price / Sales
8.27
Price / Book
5.60
EV / EBITDA
16.06
Gross margin
71.5%
Operating margin
46.5%
Net margin
35.6%
Return on equity
—
Debt / equity
0.01
Current ratio
6.39
Dividend yield
3.0%
Payout ratio
69.6%
Company profile
Exchange
Other OTC
Employees
7,872
IPO date
2012-08-03
Headquarters
Tokyo, TY, JP
About Chugai Pharmaceutical Co., Ltd.

Chugai Pharmaceutical Co., Ltd. is a prominent global pharmaceutical company, operating subsidiaries involved in the full lifecycle of drug development, from research and manufacturing to sales, import, and export, serving both Japanese and international markets. Its commercialized product portfolio spans several key therapeutic areas. These include a robust oncology offering with leading treatments like Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda. Additionally, it provides medications for bone health (e.g., Actemra, Edirol, Bonviva), renal conditions (such as Mircera and Oxarol), and neurological or other diverse ailments (including Hemlibra, CellCept, and Enspryng). Beyond its existing offerings, the company maintains an active research and development pipeline. This pipeline features multiple promising candidates targeting oncology, orthopedic and joint disorders, autoimmune diseases, kidney-related conditions, and various neurological or other health issues. Strategic partnerships are central to Chugai's operations, most notably a significant alliance with the Roche Group. The company also fosters collaborative research initiatives with academic institutions. Established in 1925, Chugai's headquarters are located in Tokyo, Japan, and it operates as a key subsidiary of Roche Holding Ltd.

More research on CHGCF
CHGCF technical analysis CHGCF TheEdge Score Compare against peers
Open full interactive analysis & DCF →